Related coverage linked through entity extraction aliases.
Jul 10, 2026
FDA approved subcutaneous isatuximab-irfc for multiple myeloma. Phase 3 EMN24 trial showed 77% MRD negativity with Isa-KRd quadruplet therapy. Phase 2 study showed 77% hematologic response rate in relapsed/refractory AL amyloidosis.
Jun 12, 2026
Updated KOMET-007 trial data show ziftomenib plus chemotherapy achieves 94% twelve-month overall survival in newly diagnosed NPM1-mutant AML. The oral menin inhibitor, approved by the FDA in November 2025 for relapsed/refractory disease, is being evaluated in a Japanese Phase II trial and a global Phase 3 study.
May 19, 2026
The FDA granted Orphan Drug Designation to Cullinan Therapeutics’ CLN-049 for relapsed/refractory AML. CLN-049 is in Phase 1 studies and had already received Fast Track designation.
Feb 24, 2026
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Feb 25, 2026
Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.
Feb 20, 2026
A Phase II trial led by WVU Cancer Institute reports the first-ever use of subcutaneous blinatumomab in CD19-positive mixed phenotype acute leukemia, with the first patient achieving complete remission after one cycle.
Feb 19, 2026
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
